Novel Immunotherapeutic Strategies of Gastric Cancer Treatment

Table 2

Major trials using anti-EGFR monoclonal antibodies.

Treatment	Enrolled patients	Disease stage	Response rate	Time to progression	Overall survival	References
Cetuximab + Cis/CPT/RT	5 EAC, 12 GEJAC	Locally advanced	13% (2/15)	NS	NS	[62]
Cetuximab + Carbo/paclitaxel/RT	45 EAC, 3 GAC, 12 SCC	Locally advanced	27% (13/49)	NS	NS	[63]
Cetuximab + Cis/docetaxel/RT	15 EAC/GEJAC, 13 SCC	Locally advanced	32% (9/28)	NS	NS	[64]
Cetuximab + FOLFOX/RT	9 AC, 18 SCC	Locally advanced	40% (4/10)	NS	NS	[65]
Cetuximab/RT	20 EAC 11 GEJAC, 9 SCC	Locally advanced	36% (13/36)	NS	NS	[66]
Cetuximab/Cis/CPT + surgery + Cetuximab/5-FU/LV/RT	20 GAC/GEJAC	Locally advanced	0% (of 18)	NS	NS	[67]
Cetuximab + FOLFIRI	4 GEJAC, 34 GAC	Metastatic; (EGFR +ve)	44% (of 34)	8 months	16 months	[68]
Cetuximab + FUFIRI	15 GEJAC, 34 GAC	Metastatic	42% (of 48)	8.5 months	16.6 months	[69]
Cetuximab + FUFOX	25 GEJAC, 27 GAC	Metastatic	65% (of 46)	7.6 months	9.5 months	[70]
Cetuximab + 5-FU/Cis verses 5-FU/Cis	32 SCC; 30 SCC	Metastatic	19%; 13%	5.7 months; 3.6 months	9.5 months; 5.5 months	[71]
Cetuximab + CI 5-FU/LV/Cis	35 GAC	Metastatic	69%	11 months	14.5 months	[72]
Cetuximab + Cis/docetaxel	8 GEJAC, 40 GAC	Unresectable/meta; static	41% (of 42)	NS	NS	[73]
Cetuximab + oxaliplatin/CPT	51 GAC	Metastatic	63% (of 35)	6.2 months	9.5 months	[74]
Cetuximab	55 EAC/GEJAC	Metastatic; (2nd-line)	2%	1.8 months	4 months	[75]
Cetuximab + Cis/CPT	1 EAC, 7 GEJAC, 1 SCC	Metastatic; (PD on Cis/CPT)	11%	1.3 months	NS	[76]
Cetuximab + docetaxel	38 NS	Metastatic; (PD on docetaxel)	6% (of 35)	2.1 months	5.2 months	[77]
Cetuximab + CPT	19 EAC/GEJAC, 8 GAC, 4 SCC	Metastatic; (PD on platinum)	6%	3.2 months	NS	[78]
Matuzumab	2 SCC	Metastatic (phase I)	1 of 2 patients with 6-month partial response			[79]
Matuzumab + ECX	5 EAC, 7 GEJAC, 9 GAC	Metastatic (phase I)	65% (of 20)	5.2 months	NS	[80]
Panitumumab	3 NS	Metastatic (phase I)	1 of 3 patients with 7-month stable disease			[81]

5-FU: 5-fluorouracil; EAC: esophageal adenocarcinoma; Carbo: carboplatin; CI: continuous infusion; Cis: cisplatin; CPT: irinotecan; ECX: epirubicin/cisplatin/capecitabine; FOLFIRI: biweekly bolus 5-FU/leucovorin, irinotecan, infusional 5-FU; FUFIRI: weekly irinotecan/leucovorin/infusional; 5-FUFUFOX: weekly oxaliplatin/leucovorin/infusional 5-FU; LV: leucovorin; GAC: gastric adenocarcinoma; GEJAC: gastroesophageal junction adenocarcinoma; N/A: not applicable; NS: not stated; ORR: objective response rate; OS: overall survival; pCR: pathologic complete response; PD: progressive disease; RT: radiation therapy; SCC: squamous cell carcinoma; TTP: time-to-progression.